INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

(d) Exhibits

Intellia Therapeutics, Inc. Exhibit
EX-99.1 2 d470529dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Intellia Therapeutics Announces Third Quarter 2017 Financial Results     •   First company to demonstrate dose-dependent CRISPR/Cas9 liver editing in non-human primates,…
To view the full exhibit click here

About INTELLIA THERAPEUTICS, INC. (NASDAQ:NTLA)

Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company’s division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company’s subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue.